157 related articles for article (PubMed ID: 16167059)
1. Risk factors of myelodysplastic syndromes: a case-control study.
Strom SS; Gu Y; Gruschkus SK; Pierce SA; Estey EH
Leukemia; 2005 Nov; 19(11):1912-8. PubMed ID: 16167059
[TBL] [Abstract][Full Text] [Related]
2. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome.
Dalamaga M; Karmaniolas K; Chamberland J; Nikolaidou A; Lekka A; Dionyssiou-Asteriou A; Mantzoros CS
Metabolism; 2013 Dec; 62(12):1830-9. PubMed ID: 24140093
[TBL] [Abstract][Full Text] [Related]
3. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
4. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population.
Lv L; Lin G; Gao X; Wu C; Dai J; Yang Y; Zou H; Sun H; Gu M; Chen X; Fu H; Bao L
Am J Hematol; 2011 Feb; 86(2):163-9. PubMed ID: 21264898
[TBL] [Abstract][Full Text] [Related]
5. Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study.
Nisse C; Lorthois C; Dorp V; Eloy E; Haguenoer JM; Fenaux P
Leukemia; 1995 Apr; 9(4):693-9. PubMed ID: 7723405
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
Ghaddar HM; Stass SA; Pierce S; Estey EH
Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes (MDS) in Central Africans.
Mukiibi JM; Paul B
Trop Geogr Med; 1994; 46(1):17-9. PubMed ID: 8165730
[TBL] [Abstract][Full Text] [Related]
8. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
10. [Chromosome abnormalities in myelodysplastic syndrome].
Fujita K; Mori H; Niikura H; Terada H; Shinohara T
Rinsho Byori; 1990 Aug; 38(8):911-6. PubMed ID: 2232253
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes (MDS) in Zimbabweans--preliminary observations.
Mukiibi JM; Paul B
East Afr Med J; 1989 Mar; 66(3):155-61. PubMed ID: 2591323
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
[TBL] [Abstract][Full Text] [Related]
13. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
14. Integrating WHO 2001-2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): a case-case analysis of benzene exposure.
Irons RD; Gross SA; Le A; Wang XQ; Chen Y; Ryder J; Schnatter AR
Chem Biol Interact; 2010 Mar; 184(1-2):30-8. PubMed ID: 19941839
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndrome: a review from University Hospital, Kuala Lumpur.
Ng SC; Kuperan P; Bosco J; Menaka N
Singapore Med J; 1990 Apr; 31(2):153-8. PubMed ID: 2196685
[TBL] [Abstract][Full Text] [Related]
16. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
17. [Study on prognostic factors in twenty-five patients with myelodysplastic syndrome].
Toyama T; Uno H; Yamashita K; Kubuki Y; Suzuki M; Maeda K; Matsuoka H; Tsubouchi H
Gan To Kagaku Ryoho; 1995 Feb; 22(2):227-32. PubMed ID: 7857097
[TBL] [Abstract][Full Text] [Related]
18. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
[TBL] [Abstract][Full Text] [Related]
19. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
[TBL] [Abstract][Full Text] [Related]
20. [A case-control study of risk factors for myelodysplastic syndromes].
Lv L; Lin GW; Wang XQ; Bao LM; Zou HJ
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2007 Dec; 25(12):705-9. PubMed ID: 18230297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
